Compare Dominion Energy Inc (D) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dominion Energy Inc vs Recursion Pharmaceuticals Inc — how do they compare? Dominion Energy Inc trades at $61.71 (market cap $54.31B), while Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B). The key difference: Dominion Energy Inc is far larger — about 25.4× Recursion Pharmaceuticals Inc's market cap, and Dominion Energy Inc pays a 4.32% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dominion Energy Inc for 76 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| D | RXRX | |
|---|---|---|
Market Cap | $54.31B | $2.14B |
Volume | 6,944,775 | 30,789,535 |
Sector | Utilities | Health |
52-Week High | $71.67 | $6.79 |
52-Week Low | $57.08 | $2.84 |
Typical Hold Time | 76 Days | 22 Days |
Enterprise Value | $108.43B | $1.66B |
Dividend Yield | 4.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $61.53, down 0.76% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with revenue growth from $14.5B in 2024 to $16.5B in 2025 and net income margin improving to 18.16%. Analyst consensus is mixed with 36% buy ratings but a $71.56 price target suggesting 16% upside. The pending merger with NextEra Energy dominates recent news coverage, creating both opportunity and regulatory uncertainty.
The stock presents a value opportunity with reasonable valuation multiples (P/E 21.37, P/S 2.96) and consistent profitability, though technical indicators suggest near-term pressure. Key risks include merger approval uncertainty, high debt levels, and interest rate sensitivity. The dividend yield of approximately 4.4% provides income support while investors await merger resolution and continued execution on data center and renewable energy investments.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
